Your browser doesn't support javascript.
loading
Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report.
Paspalj, V; Polterauer, S; Poetsch, N; Reinthaller, A; Grimm, C; Bartl, T.
Afiliação
  • Paspalj V; Division of General Gynecology and Gynecologic Oncology, Department of Obstetrics and Gynecology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Austria.
  • Polterauer S; Division of General Gynecology and Gynecologic Oncology, Department of Obstetrics and Gynecology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Austria.
  • Poetsch N; Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology, Vienna, Austria.
  • Reinthaller A; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Austria.
  • Grimm C; Division of General Gynecology and Gynecologic Oncology, Department of Obstetrics and Gynecology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Austria.
  • Bartl T; Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology, Vienna, Austria.
Gynecol Oncol Rep ; 37: 100817, 2021 Aug.
Article em En | MEDLINE | ID: mdl-34258357
ABSTRACT
•Checkpoint inhibitor therapy affecting PD-L1 as treatment for advanced solid tumors.•Success in trial pembrolizumab therapy in multiresistant metastatic choriocarcinoma.•Long-term remission after pembrolizumab therapy in multiresistant choriocarcinoma.•Only six reported cases, one with comparable follow-up and outcome.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article